Studies sex hormone levels in people with neuromyelitis optica spectrum disorder
Measures sex hormone levels in adults with neuromyelitis optica spectrum disorder in southern China.
Plain-language title generated from the registry record
Registry title: Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
Key facts
- Where
- Xiamen, ChinaSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for AQP4-IgG. It also takes healthy adults as a comparison group.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- NMOSD diagnosed by the 2021 Chinese guidelines for NMOSD diagnosis and management
- Biomarker or test result
- Positive blood test for AQP4-IgG (patient group)
Main reasons for not taking part
- Other serious body-wide diseases, such as cancer
- Severe mental illness that would stop you following the study steps or check-ups
- Past infection of the brain or spinal cord
- Severe liver or kidney problems, or failure of other vital organs
- Allergy to gadolinium-DPTA
Read by machine on 12 November 2026.
Where in China
- The First Affiliated hospital of Xiamen UniversityXiamen, ChinaContact: Jianpeng LiNo longer taking part
- The Second Affiliated Hospital of Xiamen Medical CollegeXiamen, ChinaContact: Ruiqiang PengNo longer taking part
- Xiamen Hospital of Traditional Chinese MedicineXiamen, ChinaContact: Wei YimingNo longer taking part
- Zhongshan Hospital Xiamen UniversityXiamen, ChinaContact: Xingyu ChenNo longer taking part
- Zhongshan Hospital Xiamen, Fudan UniversityXiamen, ChinaContact: Guoqiang FeiNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xiamen Hospital of Traditional Chinese Medicine
- Trial code
- NCT07266051
- Record updated
- 18 December 2025
- Original description
This study aims to characterize sex hormone alterations and their potential clinical significance in NMOSD patients from Southern China through comprehensive hormonal profiling.Read full original descriptionShow less
Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
This study aims to characterize sex hormone alterations and their potential clinical significance in NMOSD patients from Southern China through comprehensive hormonal profiling.
Inclusion: Aged 18 years or older, regardless of sex; Fulfilled the diagnostic criteria for Neuromyelitis Optica Spectrum Disorders as defined by the 2021 Chinese guidelines for the diagnosis and management of NMOSD; Seropositive for AQP4-IgG; Provided informed consent by the participant or their legal guardian; Aged 18 years or older, regardless of sex; Gender- and age-matched healthy individuals; Provided informed consent by the participant or their legal guardian.
Exclusion: Diagnosis of other serious systemic diseases (e.g., malignancy); Presence of severe psychiatric disorders that would preclude compliance with study procedures and/or follow-up assessments; History of infectious pathologies of the central nervous system; Those with severe liver and kidney function impairment or dysfunction of other vital organs; Patients with other conditions that do not allow participation in clinical research; Patients allergic to gadolinium-DPTA; Patients with other conditions that do not allow participation in clinical research.